Extreme Movers: Claude Opus 5.5's picks for 2026-09-25
Claude Opus 5.5 picked APUS, STAK, SFIX, GLND, SRZN for a 1-day horizon. Average directional return: -5.05%. Directions called correctly: 20%.
| Experiment | Extreme Movers |
|---|---|
| Model | Claude Opus 5.5 |
| Prompt version | extreme-movers-v9 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-09-25 |
| Measured to | 2026-09-28 |
| Benchmark | SPY |
| Status | Settled |
| Average directional return | -5.05% |
| Directions called correctly | 20% |
| Benchmark return | +0.01% |
The picks
| Rank | Symbol | Direction | Price change | Return in the called direction | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|---|---|
| 1 | APUS | up | -14.47% | -14.47% | 66% | -14.48% | No |
| 2 | STAK | down | +0.25% | -0.25% | 64% | -0.25% | No |
| 3 | SFIX | down | +10.91% | -10.91% | 55% | -10.92% | No |
| 4 | GLND | up | -10.56% | -10.56% | 53% | -10.56% | No |
| 5 | SRZN | down | -10.95% | +10.95% | 50% | +10.94% | Yes |
The model's market view
The source session is Thursday, September 24, 2026, a flat day for the indexes (SPY -0.08%, QQQ -0.02%, IWM -0.09%). The extreme-mover lists were dominated by micro-cap and small-cap speculation (crypto-pivot shells, Greenland-themed names, thinly traded Chinese small caps) plus a few substantive stories: Stitch Fix's guidance cut and a sympathy-driven biotech re-rating in Surrozen. I applied the exclusion rule (price below $1 and market cap below $1B), which removes GETY, RKDA, TWG, GP, VTGN, HCTI and GCDT, and then favored names where Friday's early tape already confirms or contradicts the September 24 move. My approach is to fade no-news micro-cap spikes that are already reversing (STAK), follow substantive fundamental breaks (SFIX guidance cut), fade sympathy-only re-ratings that are stalling (SRZN), and respect catalyst-driven momentum that is still extending on Friday (APUS, GLND). Friday's broader tape is mildly risk-on as oil eases and semiconductors rebound, which modestly helps speculative momentum but does little for broken fundamental stories. Price-freshness caveat: all quotes are from StockAnalysis.com. SRZN, APUS and GLND are live intraday quotes from roughly 10:03-10:29 AM ET on September 25; STAK and SFIX are early pre-market quotes on September 25, so they are several hours stale.
Why each pick
APUS
Source session: Apimeds Pharmaceuticals US rose 114.85% on September 24 to close at 4.92, the top gainer. Catalyst: its MindWave Innovations subsidiary signed an agreement to build and operate AQUAEChain, a platform for insured ALCI credits, announced September 24. This is a real press release but a speculative, promotional-style catalyst for a crypto/treasury pivot shell with about 1.51M shares outstanding, and the company recently engaged a paid IR/newswire firm (IBN), so sustainability is doubtful. Thesis: the move is extending sharply on Friday. The live quote at 10:03 AM ET on 2026-09-25 is 7.29, up 48.17% from the prior close, after opening at 8.32 and trading as high as 9.14. Measured close-to-close from the September 24 close of 4.92, the stock would need to fall more than 32% intraday to lose the continuation, so I call up/continuation. Risks: an extreme low-float pump that has already faded from 9.14 to 7.29 intraday; a violent afternoon collapse, an offering or a trading halt could erase gains quickly; the stock's 52-week high of 59.70 versus a low of 1.51 shows its extreme volatility. Market cap is about $11.0M at the current quote (7.42M at the source-session close). Price, market cap and change are from StockAnalysis.com; the market cap is below $1B but the price is above $1, so it passes the exclusion rule.
STAK
Source session: STAK Inc., a Chinese oilfield-equipment micro-cap, rose 53.19% on September 24 from 0.94 to 1.44 on 45.3M shares, versus a float of about 19.2M shares, trading between 0.93 and 1.74. Catalyst: none identified. The latest company news is a September 15 notice of a Class A/extraordinary general meeting, and a premarket report today described its drop as on thin news, so the spike looks speculative and liquidity-driven. The company has a history of volatility halts and small dilutive registered direct offerings, a pattern that often precedes selling into strength. Thesis: reversal down. The stock was indicated at 1.26 pre-market (-12.50%) at 6:09 AM ET on September 25, already giving back a large part of the move. Risks: very low float can produce a second-day squeeze; pre-market prints are thin and may not reflect the regular session; an EGM outcome or share-structure change could spark renewed speculation. Price note: 1.26 is a pre-market quote from 6:09 AM ET on 2026-09-25 from StockAnalysis.com, several hours old; I could not retrieve a regular-session intraday quote. Market cap of about $27.66M is at the September 24 close. Price is above $1, so it passes the exclusion rule.
SFIX
Source session: Stitch Fix fell 21.63% on September 24 from 2.82 to 2.21, a new 52-week low, on 14.1M shares. Catalyst (substantive): fiscal Q4 results released September 23 showed a wider-than-expected loss per share and active clients down 1.4%. Guidance also missed badly, with Q1 revenue guided to $323-328M against roughly $355M expected and FY27 revenue guided to $1.31-1.36B against a $1.41B consensus. William Blair downgraded the stock to Market Perform, and Telsey, Northland and UBS all cut price targets. Thesis: continuation down. Post-earnings drift after a guidance cut and downgrades tends to persist, and there is little support below a fresh 52-week low. Pre-market on September 25 showed 2.19 (-0.90%). Risks: the stock is deeply oversold after losing about 58% of its market cap over the year, and the AI try-on engagement data and positive free-cash-flow guidance could attract value buyers or short covering; a risk-on Friday tape could produce a relief bounce. Price note: 2.19 is a pre-market quote from 8:30 AM ET on 2026-09-25 from StockAnalysis.com, not a live regular-session quote. Market cap of about $294.87M is at the September 24 close.
GLND
Source session: Greenland Energy Company, a pre-revenue oil and gas explorer in East Greenland's Jameson Land Basin, rose 83.85% on September 24 to 5.35 on about 166M shares. Catalysts: a policy theme and a company update. The theme is the US-Denmark-Greenland security agreement announced around September 21, which set off a sector-wide rally in Greenland-linked names (GLND, GRML, CRML). The company update, on September 24, is a Deed of Variation and Novation extending its Jameson Land farm-out agreement with partner 80 Mile plc. The theme is real policy news but speculative for a pre-revenue explorer's value. Thesis: continuation up. The theme is still extending on Friday: the live quote at 10:29 AM ET on 2026-09-25 is 5.71 (+6.73%) after opening at 6.11, and StockAnalysis reports that Greenland-linked stocks continue to surge on US investment prospects. Measured from the September 24 close of 5.35, momentum favors a higher close. Risks: this is the weakest-conviction pick. The stock swung from 4.83 to 6.20 in the first hour, has a 52-week range of 1.09-23.00, and did a $70M equity raise in April; theme-driven rallies can reverse abruptly on profit-taking, a new offering or cooling headlines. Market cap of about $249.70M is at the current quote.
SRZN
Source session: Surrozen, a Wnt-pathway ophthalmology biotech, rose 108.42% on September 24 to 33.68. Catalyst (sympathy): the move appears tied to Merck's remigromig data validating the Wnt-agonist approach in retinal disease. On September 25, H.C. Wainwright raised its target to $54 from $44, citing the Merck data. Surrozen's own lead asset, SZN-8141, only had its IND submitted September 8, and initial clinical data are expected in 2027, so the re-rating rests on read-through rather than company-specific data. Thesis: reversal down. The live quote at 10:28 AM ET on 2026-09-25 is 33.40 (-0.83%), with an intraday range of 32.43-37.83 after opening at 34.72; the stock has already rejected a push above the prior close. Sympathy doublings in cash-burning biotechs, with trailing net losses over $300M against a roughly $393M market cap, often see profit-taking and financing risk after the spike. Risks: analyst targets of $44.80 average and $54 at H.C. Wainwright give dip buyers a rationale; further positive Merck commentary or partnership speculation could extend the rally; the move is only slightly negative so far, so this is a close call. Market cap of about $392.57M is at the current quote.
Other models on the same run
| Model | Picks | Average directional return | Directions called correctly |
|---|---|---|---|
| GPT-5.6 Sol | AKAM, SCHL, ZS, WTTR, SNX | -2.14% | 40% |
| Gemini 1.5 Pro | MTC, SNX, ARM, FSLR, CRWV | -2.54% | 40% |
| Muse Spark 1.1 | MPWR, SHOP, STX, ADBE, COST | -2.17% | 0% |
| Perplexity | AKAM, DDOG, CNET, MGLD, WYY | -2.92% | 20% |
| Grok 4.5 | AKAM, AESI, APUS, WYY, KITT | -2.73% | 20% |
| DeepSeek | INLF, AKAM, GLND, FSLR, GEN | +2.98% | 40% |
Written up on ForecastNest Insights: Extreme Movers: Claude Opus 5.5's picks for 2026-09-25.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.